Non-viral Gene Therapy for Stargardt Disease with ECO/pRHO-ABCA4 Self-Assembled Nanoparticles
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Stargardt disease (STGD) is an autosomal recessive retinal disorder caused by a monogenic ABCA4 mutation. Currently, there is no effective therapy to cure Stargardt disease. The replacement of mutated ABCA4 with a functional gene remains an attractive strategy. In this study, we have developed a non-viral gene therapy using nanoparticles self-assembled by a multifunctional pH-sensitive amino lipid ECO and a therapeutic ABCA4 plasmid. The nanoparticles mediated efficient intracellular gene transduction in wild-type (WT) and Abca4 −/− mice. Specific ABCA4 expression in the outer segment of photoreceptors was achieved by incorporating a rhodopsin promoter into the plasmids. The ECO/ pRHO-ABCA4 nanoparticles induced substantial and specific ABCA4 expression for at least 8 months, 35% reduction in A2E accumulation on average, and a delayed Stargardt disease progression for at least 6 months in Abca4 −/− mice. ECO/plasmid nanoparticles constitute a promising non-viral gene therapy platform for Stargardt disease and other visual dystrophies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123 · cited 1×
“Minimizing off-target transgene expression with the tissue-specific promoter is also critical to improve the safety of gene therapy.(39)”
BackgroundRussell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Schwartz, S. D., Regillo, C. D., Lam, B. L., Eliott, D., Rosenfeld, P. J., Gregori, N. Z., Hubschman, J.-P., Davis, J. L., Heilwell, G., Spirn, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61376-3 · Cited by 1,327
Brunk, U. T., & Terman, A. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00959-0 · Cited by 919
Weng, J., Mata, N. L., Azarian, S. M., Tzekov, R. T., Birch, D. G., & Travis, G. H. (1999) · Cell · doi:10.1016/s0092-8674(00)80602-9 · Cited by 881 · cited 1×
“Histochemical analysis of the retina revealed no significant differences in the retinal structure and integrity between the PBS and treated groups (Figure 5C), possibly due to the fact that the Abca4 / mouse model did not demonstrate clear retinal degeneration within the treatment period.(32,33)”
ResultLipofuscin: Mechanisms of formation and increase with age
TERMAN, A., & BRUNK, U. T. (1998) · APMIS · doi:10.1111/j.1699-0463.1998.tb01346.x · Cited by 387 · cited 1×
“Lipofuscin or A2E accumulation in the RPE is responsible for the pathological damage to the retina.(41,42) Inhibition or slowdown of A2E or lipofuscin accumulation is considered as the critical first step for preserving the retina and vision in effective treatment of Stargardt disease.”
BackgroundEffective delivery of large genes to the retina by dual AAV vectors
Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302948 · Cited by 269
A comprehensive review of retinal gene therapy
Boye, S. E., Boye, S. L., Lewin, A. S., & Hauswirth, W. W. (2013) · Molecular Therapy · doi:10.1038/mt.2012.280 · Cited by 262
Chen, Y., Okano, K., Maeda, T., Chauhan, V., Golczak, M., Maeda, A., & Palczewski, K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.315432 · Cited by 229 · cited 2×
“ABCA4 flips the orientation of membrane-bound lipids from the luminal leaflet of the outer segment disc membrane to the cytosolic side, and it transports both phosphatidylethanolamine (PE) and the all-trans-retinal (atRAL)/PE Schiff base (N-Ret-PE) into the cytosol, where atRAL is converted to all-trans-retinol (atROL…”
BackgroundSelf-citationRadu, R. A., Mata, N. L., Nusinowitz, S., Liu, X., Sieving, P. A., & Travis, G. H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737855100 · Cited by 227
Tsybovsky, Y., Molday, R. S., & Palczewski, K. (2010) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4419-5635-4_8 · Cited by 200 · cited 2×
“ABCA4 flips the orientation of membrane-bound lipids from the luminal leaflet of the outer segment disc membrane to the cytosolic side, and it transports both phosphatidylethanolamine (PE) and the all-trans-retinal (atRAL)/PE Schiff base (N-Ret-PE) into the cytosol, where atRAL is converted to all-trans-retinol (atROL…”
BackgroundSelf-citationRadu, R. A., Yuan, Q., Hu, J., Peng, J. H., Lloyd, M., Nusinowitz, S., Bok, D., & Travis, G. H. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1470 · Cited by 188
Lenis, T. L., Hu, J., Ng, S. Y., Jiang, Z., Sarfare, S., Lloyd, M. B., Esposito, N. J., Samuel, W., Jaworski, C., Bok, D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802519115 · Cited by 158 · cited 1×
“This expression is at least part of the cause of the ocular Abca4 / phenotype.(43) Therefore, RPE cells can be a potential target to rescue abca4-mediated retinal degenerations.”
BackgroundDNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice
Han, Z., Conley, S. M., Makkia, R. S., Cooper, M. J., & Naash, M. I. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64833 · Cited by 150
Dyka, F. M., Boye, S. L., Chiodo, V. A., Hauswirth, W. W., & Boye, S. E. (2014) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.212 · Cited by 128
Binley, K., Widdowson, P., Loader, J., Kelleher, M., Iqball, S., Ferrige, G., de Belin, J., Carlucci, M., Angell-Manning, D., Hurst, F., et al. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-11871 · Cited by 115 · cited 1×
“Acceptable safety was demonstrated for the lentivirus despite the concern of uncontrolled integration into the genome and oncogenic effects of retroviruses.(36)”
BackgroundAn AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 −/− Mice
McClements, M. E., Barnard, A. R., Singh, M. S., Charbel Issa, P., Jiang, Z., Radu, R. A., & MacLaren, R. E. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.156 · Cited by 92
Sun, D., Sahu, B., Gao, S., Schur, R. M., Vaidya, A. M., Maeda, A., Palczewski, K., & Lu, Z.-R. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.02.005 · Cited by 47
Self-citation
Cited by
Han, H., Li, S., Xu, M., Zhong, Y., Fan, W., Xu, J., Zhou, T., Ji, J., Ye, J., & Yao, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114770 · Cited by 322
Gautam, M., Jozic, A., Su, G. L.-N., Herrera-Barrera, M., Curtis, A., Arrizabalaga, S., Tschetter, W., Ryals, R. C., & Sahay, G. (2023) · Nature Communications · doi:10.1038/s41467-023-42189-3 · Cited by 123
Therapy Approaches for Stargardt Disease
Piotter, E., McClements, M. E., & MacLaren, R. E. (2021) · Biomolecules · doi:10.3390/biom11081179 · Cited by 49
Siles, L., Ruiz-Nogales, S., Navinés-Ferrer, A., Méndez-Vendrell, P., & Pomares, E. (2023) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2023.02.032 · Cited by 29
Siles, L., & Pomares, E. (2025) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2025.102482 · Cited by 4
Metadata
- Authors
- Sun, D., Schur, R. M., Sears, A. E., Gao, S.-Q., Vaidya, A., Sun, W., Maeda, A., Kern, T., Palczewski, K., & Lu, Z.-R.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 28
- Issue
- 1
- Pages
- 293-303
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2972310174
- Cited by
- 54
- References
- 18
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.